In a recent paper, Versluis et al.
In a recent paper, Versluis et al. 1 reported on hepatitis E virus (HEV) hepatitis as an emerging infectious diseases in adult recipients of hematopoietic SCT (HSCT). Recently, we reported on chronic HEV hepatitis in children, both in liver transplantation and in a HSCT recipient. 2, 3 The HSCT child ultimately died from hepatic complications. 2 We concur with Versluis et al. that HEV is an underestimated and under recognized etiology for chronic hepatitis in the immunocompromised patient. The lack of data on HEV seroprevalence, especially in children, and our recent cases of HEV infection prompted us to estimate the seroprevalence of this virus in a pediatric population awaiting HSCT.
We recruited children who had undergone HSCT for underlying hematological malignancies or primary immunodeficiency. Inclusion criteria were: age between 1 month and 19 years, and presenting with elevated serum aminotransferase values after HSCT (ALT ⩾ 60 IU/L; AST ⩾ 100 IU/L). As a control group, children without liver or chronic diseases were recruited from the Infectious Disease outpatient clinic and the home intravenous antibiotic program. Samples were tested for anti-HEV IgG and anti-HEV IgM reactivity as previously described. 3 We found an overall HEV IgG seroprevalence of 13.3% in our pediatric cohort of HSCT patients (Table 1) . Of 75 patients undergoing allogeneic HSCT between January 2008 and December 2010, 63 had elevated aminotransferases and of those, 45 had available sera for serological tests. Six patients tested positive for anti-HEV IgG. The median age of HEV positive children was 7 years and 2 patients were younger than 1 year of age. All seropositive patients were born in Canada. Four of them lived in rural and two in urban areas. In the control group, HEV IgG seroprevalence was 6.9%. All sera were found to be negative for anti-HEV IgM in both groups.
The seroprevalence in our control population is higher than the 3% IgG seropositivity previously described in a Canadian study. 4 Most children in our control group lived in urban areas with high cultural diversity, a factor that may have influenced the seroprevalence.
In our HSCT pediatric population, the seroprevalence is similar to that described in a German cohort of immunocompromised adults 5 and by Versluis et al. 1 The high HEV seroprevalence observed in our HSCT population could be explained by the selection criteria, which included only patients with elevated serum aminotransferases levels. It could also stem from the transfusion of blood products 6 or the transfer of maternal antibodies in younger patients (⩽1-year-old). 7, 8 In conclusion, the high seroprevalence found by Versluis et al. and confirmed in our subgroup of HSCT children suggests that HEV infection is a more common opportunistic infection than previously suggested, both in children and adults. Altogether, these studies strengthen the indication for anti-HEV screening before transplant, especially in cases where peri-transplant transmission is highly suspected. 9 Moreover, they suggest that HEV infection should be considered as an etiology of liver dysfunction in immunocompromised children. 10 Abbreviations: HEV = hepatitis E virus; HSC = hematopoietic stem cell; MDS = myelodysplastic syndrome; PID = primary immunodeficiency.
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